Nordic Capital Fund VII and Avista Capital Partners Agree to Acquire Bristol-Myers Squibb ConvaTec Business for approximately $4.1 Billion
More News related to BMY
- Grant & Eisenhofer Boosts Antitrust Practice with Addition of Linda Nussbaum and John Radice
- Pcubed Strengthens its Board as it Prepares for More Global Growth
- Notable Analyst Rating Changes 08/31: GPS, ANF, BMY, UBS Upgraded; HPQ, DGIT, RAX, POT Downgraded
- Jefferies Upgrades Bristol-Myers (BMY) to Buy
- ZymoGenetics (ZGEN) Completes Enrollment in PEG-Interferon Lambda and Ribavirin Phase 2b
More News related to Mergers and Acquisitions
- National Fuel Gas (NFG) Announces Sale of Landfill Gas Business to Toro Energy GP II; Adjustes GAAP EPS to Reflect Sale
- TransDigm Group (TDG) Completes $74M Acquisition of Semco Instruments
- EOG Resources (EOG) has hired BMO Capital to sell Gulf of Mexico Assets, Bloomberg
- JS Acquisition Extends $2.40/Share Tender Offer for Emmis Communications (EMMS)
- MeadWestvaco (MWV) Announces $68M Sale of Media and Ent. Business to Atlas Holdings
Bristol-Myers Squibb Company (NYSE: BMY) announced it has signed a definitive agreement to sell its ConvaTec business unit to Nordic Capital Fund VII and Avista Capital Partners ("Avista") for $4.1 billion subject to adjustments based on ConvaTec's audited 2007 financial statements and closing working capital. ConvaTec is a world leader in the development and marketing of innovative wound therapeutics and ostomy care products. [jt]
Create E-mail AlertRelated Categories
Mergers and AcquisitionsStocks Mentioned
+0.15Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
